Literature DB >> 16086227

Cost-effectiveness of positron emission tomography in breast cancer.

J Scott Sloka1, Peter D Hollett, Maria Mathews.   

Abstract

PURPOSE: In this study, we used quantitative decision tree modeling to assess the cost-effectiveness of a positron emission tomography (PET)-based management scenario for breast cancer in Canada. PROCEDURES: Two patient management scenarios were compared (with and without PET). A metaanalysis of studies for the accuracy of PET in staging breast cancer was conducted. Life expectancies were calculated. Management costs were determined from previous cost-effective analyses, management costs from our institutions, and recently published Canadian cost estimates of various procedures.
RESULTS: A cost savings of $695 per person is expected for the PET strategy, with an increase in life expectancy (7.4 days), when compared with the non-PET strategy. This cost savings remained in favor of the PET strategy when subjected to a sensitivity analysis.
CONCLUSIONS: The use of a PET management strategy for the staging of breast cancer is expected to remain economically viable in Canada under various economic conditions.

Entities:  

Mesh:

Year:  2005        PMID: 16086227     DOI: 10.1007/s11307-005-0012-5

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  50 in total

1.  MD@: a physician-friendly decision analysis tool.

Authors:  S S Gambhir; P Gupta; J E Shepherd; M A Allen; C Hoh; J Maddahi; M E Phelps
Journal:  MD Comput       Date:  1998 Jan-Feb

2.  Isolated regional lymph node dissection: morbidity, mortality and economic considerations.

Authors:  K I Bland; T W Klamer; H C Polk; C O Knutson
Journal:  Ann Surg       Date:  1981-03       Impact factor: 12.969

3.  Decision analysis in nuclear medicine.

Authors:  S S Gambhir
Journal:  J Nucl Med       Date:  1999-09       Impact factor: 10.057

4.  Importance of the level of axillary involvement in relation to traditional variables in the prognosis of breast cancer.

Authors:  S Zurrida; A Morabito; V Galimberti; A Luini; M Greco; C Bartoli; R Raselli; N Rossi; G Vessecchia; N Cascinelli; U Veronesi
Journal:  Int J Oncol       Date:  1999-09       Impact factor: 5.650

5.  The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease.

Authors:  N Y Tse; C K Hoh; R A Hawkins; M J Zinner; M Dahlbom; Y Choi; J Maddahi; F C Brunicardi; M E Phelps; J A Glaspy
Journal:  Ann Surg       Date:  1992-07       Impact factor: 12.969

6.  Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer.

Authors:  J M Ververs; R M Roumen; A J Vingerhoets; G Vreugdenhil; J W Coebergh; M A Crommelin; E J Luiten; O J Repelaer van Driel; M Schijven; J C Wissing; A C Voogd
Journal:  Eur J Cancer       Date:  2001-05       Impact factor: 9.162

7.  Clinical practice guidelines for the care and treatment of breast cancer: mastectomy or lumpectomy? The choice of operation for clinical stages I and II breast cancer (summary of the 2002 update).

Authors:  Hugh Scarth; Jacques Cantin; Mark Levine
Journal:  CMAJ       Date:  2002-07-23       Impact factor: 8.262

8.  Health-adjusted life expectancy.

Authors:  M C Wolfson
Journal:  Health Rep       Date:  1996       Impact factor: 4.796

9.  [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer.

Authors:  H Minn; I Soini
Journal:  Eur J Nucl Med       Date:  1989

10.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.

Authors:  S S Gambhir; C K Hoh; M E Phelps; I Madar; J Maddahi
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

View more
  4 in total

1.  Cost-effectiveness of Fluorine-18-Fluorodeoxyglucose positron emission tomography in tumours other than lung cancer: A systematic review.

Authors:  Salvatore Annunziata; Carmelo Caldarella; Giorgio Treglia
Journal:  World J Radiol       Date:  2014-03-28

2.  MRI and ¹⁸F-FDG PET/CT in monitoring the response to neoadjuvant chemotherapy: is it necessary to appropriately select the patients?

Authors:  Laura Evangelista; Domenico Ruggieri; Luigi Pescarini; Giorgio Saladini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08       Impact factor: 9.236

Review 3.  PET/MRI: Where might it replace PET/CT?

Authors:  Eric C Ehman; Geoffrey B Johnson; Javier E Villanueva-Meyer; Soonmee Cha; Andrew Palmera Leynes; Peder Eric Zufall Larson; Thomas A Hope
Journal:  J Magn Reson Imaging       Date:  2017-03-30       Impact factor: 4.813

Review 4.  A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?

Authors:  Astrid Langer
Journal:  BMC Health Serv Res       Date:  2010-10-08       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.